Australian-New Zealand Clinical Trial: An Australasian Leukaemia and Lymphoma Group (ALLG) phase II, multicenter, open-label trial evaluating the efficacy and safety of ELVN-001 in patients With Chronic Myeloid Leukemia (CML).

Australia, Oct. 15 -- The Australian New Zealand Clinical Trials Registry (ANZCTR) received information related to the study titled ‘An Australasian Leukaemia and Lymphoma Group (ALLG) phase II, multicenter, open-label trial evaluating the efficacy and safety of ELVN-001 in patients With Chronic Myeloid Leukemia (CML).’. The following are the other relevant details related to the trial:

Trial ID: 392726

Submit Date: 9/24/26 15:17

Study Type: Interventional

Intervention: Patients will receive an oral tablet (80mg) of ELVN-001 given once a day with a large glass of water at the same time each day. Treatment cycles are for 28 days and administered continuously. The total treatment duration is about 4-5 years. Participants will be eligible ...